Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active Controlled Trial, Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension Over a 3-Month Period, Followed by a 12-Month Follow-Up With Open-Label DE-130A Treatment.

NCT04133311 is registered in ClinicalTrials.gov with Santen SAS as lead sponsor.

NCT NCT04133311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04133311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active Controlled Trial, Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension Over a 3-Month Period, Followed by a 12-Month Follow-Up With Open-Label DE-130A Treatment.
Lead sponsor
Santen SAS
Phase
Phase 3
Overall status
Completed
Start date
April 10, 2019
Completion date
October 26, 2022
Enrollment
386 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular surface disease, open-angle glaucoma or ocular hypertension